Company Filing History:
Years Active: 1995-1996
Title: The Innovations of Bernhard Sczepanik
Introduction
Bernhard Sczepanik is a prominent inventor based in Bundesrepublik, Germany. With a focus on pharmaceuticals, he has been instrumental in developing innovative solutions aimed at enhancing drug delivery methods. Throughout his career, he has been awarded two patents, showcasing his commitment to advancing the field of medicine.
Latest Patents
Bernhard's latest patents include a novel slow-release pharmaceutical preparation. This method allows for the preparation of pharmaceutical compositions intended for oral administration without the use of organic solvents. The key innovation lies in employing solidified melt granulates of an active ingredient mixed with a meltable auxiliary substance. This auxiliary is soluble in the active ingredient when exposed to elevated temperatures, facilitating effective medication delivery. Another notable patent focuses on an orally administered solvent-free pharmaceutical preparation with delayed release, further solidifying his expertise in the field.
Career Highlights
Throughout his career, Bernhard Sczepanik has made significant contributions to the pharmaceutical industry. He has worked with recognized firms such as Schwarz Pharma AG and Schwartz Pharma AG, where he honed his skills and expanded his knowledge in pharmaceutical development. His innovative spirit and commitment to improving drug formulations have set a benchmark in the industry.
Collaborations
Bernhard has had the opportunity to collaborate with distinguished professionals in the field, including Ulrich Munch and Hans-Jurgen Mika. These partnerships have enriched his projects and allowed for the sharing of diverse expertise, fostering an environment of innovation.
Conclusion
In summary, Bernhard Sczepanik is a distinguished inventor with a focus on pharmaceutical preparations. His two patents reflect his aptitude and dedication to creating effective solutions in medication delivery. Through collaboration and a strong career foundation, he continues to impact the pharmaceutical industry positively.